SOCRA CCRP — Certified Clinical Research Professional — Questions and Answers

Question 1: A sponsor is implementing Risk-Based Monitoring (RBM). Which factor would MOST likely increase the frequency of on-site monitoring for a particular site?

The site has enrolled fewer than average subjects
The PI has more than 10 years of clinical trial experience
The site has a high rate of protocol deviations and late adverse event reporting (Correct answer)
The site has a consistently low query rate

Correct answer: The site has a high rate of protocol deviations and late adverse event reporting

High protocol deviation rates and late SAE reporting are risk signals that indicate the site needs more intensive on-site oversight.

Question 2: Under 21 CFR Part 312, which of the following is the sponsor's responsibility regarding IP shipped to investigator sites?

Sponsors must personally deliver IP to each investigator
Sponsors may ship IP to investigators before IND submission is complete
Sponsors are not responsible once IP leaves the manufacturing facility
Sponsors must ship IP only to investigators under an IND and maintain shipping records (Correct answer)

Correct answer: Sponsors must ship IP only to investigators under an IND and maintain shipping records

21 CFR 312.50 requires sponsors to ship IP only to qualified investigators holding a valid IND and to maintain complete shipping records for regulatory review.

Question 3: What must be documented when an investigator delegates a study task to a site staff member?

Only the staff member's name and date
A verbal agreement witnessed by a third party
The sponsor's written approval of that staff member
The specific tasks delegated, start/stop dates, and staff member's signature (Correct answer)

Correct answer: The specific tasks delegated, start/stop dates, and staff member's signature

The Delegation of Authority log must capture the specific tasks delegated, effective dates, and the delegatee's signature acknowledging the delegation.

Question 4: What is a site initiation visit (SIV)?

A close-out visit
A visit only for problems
A social gathering
A visit to train staff, review the protocol, set up systems, and confirm enrollment readiness (Correct answer)

Correct answer: A visit to train staff, review the protocol, set up systems, and confirm enrollment readiness

The SIV prepares the site by training staff, reviewing procedures, setting up systems, and confirming readiness.

Question 5: When a temperature excursion is discovered for stored investigational product, what is the correct immediate action?

Continue using the IP if it looks and smells normal
Discard the affected IP immediately to prevent protocol deviations
Report the excursion only at the next monitoring visit
Quarantine the affected IP and notify the sponsor before using or dispensing it (Correct answer)

Correct answer: Quarantine the affected IP and notify the sponsor before using or dispensing it

Upon discovering a temperature excursion, the site must immediately quarantine the affected IP so it cannot be accidentally dispensed. The sponsor must be notified promptly because only the sponsor—or their designee—can evaluate stability data and determine whether the affected product is still acceptable for use.

Question 6: A participant in a double-blinded trial presents to an outside emergency room with a life-threatening condition. The treating physician believes knowing the treatment assignment is critical for patient care. According to standard procedures, who holds the primary authority and mechanism to grant an emergency unblinding request?

The lead research pharmacist at the investigational site.
The Sponsor or their designated representative (e.g., medical monitor). (Correct answer)
The Chairperson of the Institutional Review Board (IRB).
The Principal Investigator, who can unblind at their sole discretion.

Correct answer: The Sponsor or their designated representative (e.g., medical monitor).

The sponsor holds the randomization code for the entire study and is responsible for establishing and maintaining the procedure for emergency unblinding. While the PI would facilitate the request, the formal process requires contacting the sponsor (or a 24/7 service designated by them) who can officially break the blind for a specific participant when it is medically necessary. This ensures the integrity of the overall study is protected while prioritizing subject safety.

Question 7: Which of the following best describes FDA's 'clinical hold' authority under 21 CFR 312.42?

A request for additional preclinical data before IND approval
An order to pause subject enrollment pending safety review
An FDA order to delay or suspend a clinical investigation for safety or compliance reasons (Correct answer)
A temporary suspension of IND review while FDA requests more information

Correct answer: An FDA order to delay or suspend a clinical investigation for safety or compliance reasons

A clinical hold under 21 CFR 312.42 is an FDA order to delay initiation or suspend an ongoing clinical investigation when safety or compliance concerns exist.

Question 8: Under 21 CFR Part 11, which requirement is essential for electronic source records to be considered trustworthy in a clinical trial?

A secure, computer-generated, time-stamped audit trail must capture all entries and changes to electronic records (Correct answer)
Electronic records must be printed to paper and countersigned by the PI within 48 hours
All electronic source data must be reviewed and locked by the sponsor within 30 days of entry
Electronic records must be backed up to offline physical media on a weekly schedule

Correct answer: A secure, computer-generated, time-stamped audit trail must capture all entries and changes to electronic records

21 CFR Part 11 mandates a secure, computer-generated, time-stamped audit trail that independently records operator actions — creation, modification, or deletion — without the ability to be altered. This ensures data integrity and supports regulatory inspection of the full data history.

Question 9: Which of the following is a disclosure of financial interests form?

21 Cfr 312
FDA Form 3455 (Correct answer)
3500, Fda 3500
Form 3454

Correct answer: FDA Form 3455

FDA Form 3455 is the correct form for disclosing financial interests in clinical research. This form is mandated by 21 CFR Part 54 and requires clinical investigators to report any financial arrangements that could potentially influence the outcome of a study. Its use helps ensure transparency and mitigate conflicts of interest in clinical trials.

Question 10: How should IP be dispensed?

No documentation needed
Per protocol and randomization, with documentation of subject, product, quantity, date, and lot number (Correct answer)
Participants take whatever they want
Only nurses dispense

Correct answer: Per protocol and randomization, with documentation of subject, product, quantity, date, and lot number

IP must be dispensed only to enrolled subjects per protocol and randomization with complete documentation.

Question 11: Under ICH E6(R2) GCP, which party bears ultimate responsibility for the conduct and integrity of a clinical trial?

The sponsor (Correct answer)
The principal investigator
The contract research organization (CRO)
The IRB/IEC

Correct answer: The sponsor

Under ICH E6(R2), the sponsor bears ultimate responsibility for the trial, although they may delegate duties to a CRO.

Question 12: What information is required on the label of an investigational product supplied to a clinical site?

A statement identifying the product as investigational, the protocol number, and storage conditions at minimum (Correct answer)
The sponsor's trade name and marketing authorization number
The retail price and insurance billing code
The subject's full name and home address

Correct answer: A statement identifying the product as investigational, the protocol number, and storage conditions at minimum

Regulatory requirements (21 CFR 312.6; ICH E6) mandate that IP labels include a statement such as 'Caution: New Drug—Limited by Federal Law to Investigational Use,' the protocol number, and required storage conditions. Labels must not identify the blinded treatment in masked studies.

Question 13: What is the distinction between a 'protocol amendment' and a 'protocol deviation' in an FDA-regulated clinical trial?

An amendment is a planned prospective change approved before implementation; a deviation is an unplanned departure from the protocol (Correct answer)
An amendment is unplanned; a deviation is planned and pre-approved by the sponsor
There is no regulatory distinction between the two terms
Amendments require FDA approval; deviations require only IRB notification

Correct answer: An amendment is a planned prospective change approved before implementation; a deviation is an unplanned departure from the protocol

A protocol amendment is a prospective, approved change to the study design, while a protocol deviation is an unplanned departure that has already occurred and must be documented and reported.

Question 14: FDA's expedited review procedure under 21 CFR 56.110 may be used when research involves:

Minor increases over minimal risk in vulnerable populations
Any study with fewer than 100 participants
Research that presents no greater than minimal risk and appears on FDA's list of eligible categories (Correct answer)
Phase I studies in healthy volunteers only

Correct answer: Research that presents no greater than minimal risk and appears on FDA's list of eligible categories

Expedited review is permitted when research presents no more than minimal risk AND the activities fall within categories identified by the Secretary of HHS.

Question 15: Which of the following actions constitutes a 'major protocol deviation' that must be reported to the sponsor and IRB in an FDA-regulated trial?

Using a centrifuge that is 30 minutes overdue for calibration
Administering study drug to a subject who did not meet an eligibility criterion (Correct answer)
A missing signature on a non-critical source document
A 2-hour delay in a non-critical study visit

Correct answer: Administering study drug to a subject who did not meet an eligibility criterion

Enrolling a subject who fails to meet eligibility criteria is a major protocol deviation because it directly affects subject safety and the integrity of the study data requiring mandatory reporting.

Question 16: A subject on a double-blind trial self-reports taking their IP with grapefruit juice, which is prohibited per protocol. This should be documented as:

An unscheduled visit note only
A protocol deviation related to IP administration (Correct answer)
A manufacturing defect
A serious adverse event

Correct answer: A protocol deviation related to IP administration

Ingesting IP with a prohibited substance is a protocol deviation that must be documented and may affect subject safety monitoring and data integrity.

Question 17: What are clinical trial registration requirements under FDAAA 801?

Entirely voluntary
Applicable clinical trials must be registered on ClinicalTrials.gov with results reporting (Correct answer)
Only sponsor-initiated
Only Phase I trials

Correct answer: Applicable clinical trials must be registered on ClinicalTrials.gov with results reporting

FDAAA Section 801 requires applicable clinical trials to be registered and submit results within specified timeframes.

Question 18: According to FDA regulations (21 CFR 312.32), which of the following outcomes makes an adverse event classified as 'serious'?

Requires an unscheduled outpatient clinic visit
Results in persistent or significant disability or incapacity (Correct answer)
Causes mild nausea lasting more than 24 hours
Causes temporary fatigue or lethargy

Correct answer: Results in persistent or significant disability or incapacity

An SAE is one that results in death, is life-threatening, requires inpatient hospitalization, causes persistent or significant disability, is a congenital anomaly, or is medically significant.

Question 19: If a subject's primary source data exists in hospital records held by an institution, what is the investigator's responsibility?

The investigator must transfer all hospital records to the sponsor at study close-out
The investigator must copy all hospital records into the investigator site file
The investigator has no responsibility for records held by the institution
The investigator must ensure the sponsor's monitor can access those records for SDV, as permitted by applicable regulations (Correct answer)

Correct answer: The investigator must ensure the sponsor's monitor can access those records for SDV, as permitted by applicable regulations

The investigator is responsible for ensuring monitors can access source data needed for verification, within the constraints of privacy and confidentiality agreements.

Question 20: Which of the following is 21 CFR 56.106 Subpart B?

Registration (Correct answer)
Licensure
Certification
Fda Form 3455

Correct answer: Registration

21 CFR 56.106, found within Subpart B, specifically addresses the 'Registration' requirements for Institutional Review Boards (IRBs). This regulation mandates that IRBs that review FDA-regulated research must register with the FDA. This registration process helps the FDA track and oversee IRBs to ensure they meet regulatory standards for protecting human subjects.

Question 21: What is the primary purpose of the 'comprehension' element in the Belmont Report's informed consent framework?

To test subjects' knowledge of clinical research regulations
To ensure information is presented in a way subjects can actually understand (Correct answer)
To verify subjects have no cognitive impairments
To ensure subjects can read at a graduate level

Correct answer: To ensure information is presented in a way subjects can actually understand

Comprehension requires that information be presented in a manner appropriate to the subject's capacity, using language they understand.

Question 22: Who is responsible for maintaining the Investigator Site File (ISF)?

The sponsor's CRA
The principal investigator and site staff (Correct answer)
The IRB
The FDA district office

Correct answer: The principal investigator and site staff

The principal investigator and site study team are responsible for maintaining the ISF (also called the Investigator's File or Regulatory Binder) at the investigative site.

Question 23: Which scenario would most likely require the IRB to suspend or terminate a study under 21 CFR 56.113?

Unexpected serious harm is occurring to subjects (Correct answer)
A subject misses a study visit
The investigator submits a late protocol deviation report
A CRC leaves the research team

Correct answer: Unexpected serious harm is occurring to subjects

The IRB has authority to suspend or terminate research when unexpected serious harm to subjects is identified, as required under 21 CFR 56.113.

Question 24: Under 21 CFR 312.32, non-fatal, non-life-threatening unexpected SUSARs must be reported to the FDA within:

15 calendar days (Correct answer)
30 calendar days
60 calendar days
7 calendar days

Correct answer: 15 calendar days

Non-fatal, non-life-threatening unexpected SUSARs must be reported to the FDA within 15 calendar days of the sponsor's first awareness.

Question 25: A clinical investigator holds equity in the company sponsoring the trial they are conducting. This situation is best described as:

A violation of GCP that automatically disqualifies the investigator
An acceptable arrangement provided it is disclosed to the sponsor
A minor administrative issue requiring no action
A financial conflict of interest that must be disclosed to the IRB and managed appropriately (Correct answer)

Correct answer: A financial conflict of interest that must be disclosed to the IRB and managed appropriately

Financial interests in a sponsor company represent a conflict of interest that must be disclosed and managed to protect research integrity and participant safety.

Question 26: The Code of Federal Regulations that applies to Electronic Records; Electronic Signatures is..

21CFR812
21CFR11 (Correct answer)
21CFR312
21CFR56

Correct answer: 21CFR11

21 CFR Part 11 is the Code of Federal Regulations that governs electronic records and electronic signatures for FDA-regulated industries. It establishes the criteria under which electronic records and signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. Compliance with 21 CFR Part 11 is essential for maintaining data integrity and regulatory compliance in clinical research.

Question 27: An investigator is disqualified by FDA under 21 CFR Part 312.70. What is the primary effect of this action?

The investigator's medical license is automatically revoked
All previously generated data from that investigator are automatically excluded from all NDAs
The investigator is fined $500,000 per violation
The investigator is prohibited from receiving investigational drugs and conducting FDA-regulated studies (Correct answer)

Correct answer: The investigator is prohibited from receiving investigational drugs and conducting FDA-regulated studies

FDA disqualification under 21 CFR 312.70 bars the investigator from receiving investigational drugs and participating in FDA-regulated research.

Question 28: During a routine on-site monitoring visit, a Clinical Research Associate (CRA) is responsible for all of the following activities EXCEPT:

Comparing data in the source documents with the entries in the Case Report Forms (CRFs).
Issuing an official FDA Form 483 for observed regulatory non-compliance. (Correct answer)
Checking the storage conditions and accountability of the investigational product.
Verifying that informed consent was obtained prior to any study-specific procedures.

Correct answer: Issuing an official FDA Form 483 for observed regulatory non-compliance.

Issuing a Form FDA 483, which lists inspectional observations, is a function reserved for an FDA inspector at the conclusion of a regulatory inspection. [16, 20] A CRA's role is to identify and help correct issues, but they do not have the regulatory authority to issue this form.

Question 29: According to ICH GCP E6(R2), which of the following is a primary responsibility of the clinical trial Sponsor?

Selecting qualified investigators and ensuring proper monitoring of the trial. (Correct answer)
Ensuring the accuracy of source data at the investigational site.
Obtaining informed consent from trial participants.
Making medical decisions for subjects during the trial.

Correct answer: Selecting qualified investigators and ensuring proper monitoring of the trial.

ICH GCP E6(R2) Section 5 clearly outlines the sponsor's responsibilities. Section 5.6 specifies that the sponsor is responsible for selecting qualified investigators and institutions. Furthermore, Section 5.18 details the sponsor's responsibility for ensuring adequate trial monitoring to verify the protection of human subjects and the quality of the data. While the investigator is responsible for obtaining consent and ensuring data accuracy at the site, the ultimate oversight and qualification assessment lies with the sponsor.

Question 30: Risk-based monitoring (RBM) approaches may use targeted SDV instead of 100% SDV. What does targeted SDV prioritize?

Checking all financial records before verifying clinical data
Verifying only the last CRF page of each subject
Reviewing only safety reports and adverse event data
Focusing verification efforts on critical data fields and higher-risk sites based on data signals and risk assessment (Correct answer)

Correct answer: Focusing verification efforts on critical data fields and higher-risk sites based on data signals and risk assessment

Targeted SDV concentrates monitoring resources on the most critical data elements and higher-risk areas identified through ongoing risk assessment.

Question 31: How should corrections be made to source documents?

Use white-out
A single line through the error, with correction, date, and initials (Correct answer)
Completely obliterate errors
Replace pages with errors

Correct answer: A single line through the error, with correction, date, and initials

Draw a single line through the error (keep it readable), write the correction, add date and initials.

Question 32: During an FDA inspection, an investigator is found to have multiple unreported protocol deviations. What is the MOST likely consequence?

An FDA Form 483 observation, a Warning Letter, or potential disqualification of the investigator (Correct answer)
A routine warning letter with no further action required
Immediate suspension of the IND by the sponsor
Automatic approval of a protocol amendment

Correct answer: An FDA Form 483 observation, a Warning Letter, or potential disqualification of the investigator

Failure to report protocol deviations can result in FDA 483 inspectional observations, Warning Letters, or investigator disqualification proceedings under 21 CFR Part 312.

Question 33: When may an IRB waive the requirement to obtain parental permission for research involving children?

Never — parental permission is always required
When the children are over 10 years old
When the study sponsor requests a waiver
When the research involves no more than minimal risk and the waiver would not adversely affect subjects' rights (Correct answer)

Correct answer: When the research involves no more than minimal risk and the waiver would not adversely affect subjects' rights

The IRB may waive parental permission when the research involves no more than minimal risk and the waiver would not adversely affect the rights and welfare of subjects.

Question 34: A clinical investigator is participating in a pivotal Phase III drug trial intended to support a marketing application. According to 21 CFR Part 54, the investigator must provide the sponsor with sufficient financial information. The investigator must promptly update this information if any relevant changes occur during the investigation and for what period of time following the completion of the study?

For 6 months following study completion.
For 1 year following study completion. (Correct answer)
For 2 years following study completion.
There is no requirement to update after study completion.

Correct answer: For 1 year following study completion.

According to 21 CFR 54.4(b), the investigator is required to provide the sponsor with accurate financial information and must 'promptly update this information if any relevant changes occur in the course of the investigation or for 1 year following completion of the study.' This ensures that the sponsor has current information when submitting the marketing application to the FDA.

Question 35: What is the Common Technical Document (CTD) format?

A format for consent documents
A standardized format for regulatory submissions organized into five modules (Correct answer)
A reporting format for adverse events
A template for protocols

Correct answer: A standardized format for regulatory submissions organized into five modules

The CTD is an internationally agreed-upon format for regulatory submissions organized into five modules.

Question 36: During a monitoring visit, the CRA finds that the drug accountability log shows 5 units dispensed but only 3 subject records document dispensing. What is this discrepancy called?

A SUSAR
A drug accountability discrepancy requiring investigation (Correct answer)
A protocol deviation
An acceptable rounding error

Correct answer: A drug accountability discrepancy requiring investigation

Any mismatch between IP dispensed per accountability records and subject-level documentation must be investigated and reconciled as a drug accountability discrepancy.

Question 37: How does centralized monitoring complement on-site monitoring?

Replaces on-site entirely
Uses statistical analyses and data reviews to detect anomalies and site performance issues remotely (Correct answer)
Only for Phase IV
Only monitors finances

Correct answer: Uses statistical analyses and data reviews to detect anomalies and site performance issues remotely

Centralized monitoring uses statistical analyses and remote review to identify potential issues across sites.

Question 38: A site receives a sponsor letter stating that a protocol deviation involving incorrect IP storage temperatures was identified. The sponsor concludes the IP is still acceptable for use. What should the site do NEXT?

Notify the FDA independently of the sponsor's conclusion
Continue using the IP without any additional action since the sponsor approved it
Dispose of all affected IP immediately without further documentation
Document the deviation and the sponsor's assessment in the site's deviation log and regulatory binder (Correct answer)

Correct answer: Document the deviation and the sponsor's assessment in the site's deviation log and regulatory binder

Even when the sponsor approves continued use of IP after a storage deviation, the site must document both the deviation and the sponsor's disposition decision in the deviation log and regulatory binder per GCP requirements.

Question 39: What is 'therapeutic misconception' in the context of informed consent?

When sponsors misrepresent study benefits in advertising
When subjects believe placebos will cure their disease
When investigators withhold treatment information
When subjects confuse research participation with receiving individualized medical care (Correct answer)

Correct answer: When subjects confuse research participation with receiving individualized medical care

Therapeutic misconception occurs when subjects fail to understand that the goal of research is to generate generalizable knowledge, not to optimize their individual care.

Question 40: A subject in a trial for an investigational antidepressant reports developing a mild rash two weeks after starting the drug. The subject has a known history of seasonal allergies and recently started using a new laundry detergent. In assessing this adverse event, what is the MOST critical determination the investigator must make for safety reporting purposes?

If the event needs to be reported to the FDA via MedWatch by the site.
The likelihood that the event is related to the investigational product (causality). (Correct answer)
The exact date the new laundry detergent was first used.
Whether the event meets the criteria for 'serious.'

Correct answer: The likelihood that the event is related to the investigational product (causality).

The investigator's assessment of causality (i.e., whether there is a reasonable possibility that the drug caused the event) is critical. This determination transforms an 'adverse event' into a 'suspected adverse reaction', which is the basis for expedited safety reporting by the sponsor to the FDA. While seriousness is also important, causality is the key factor that links the event to the drug for regulatory reporting.

Question 41: What is a pre-study (site qualification) visit?

An evaluation of whether a site has adequate facilities, personnel, and patient population (Correct answer)
A post-study visit
A launch celebration
A financial meeting

Correct answer: An evaluation of whether a site has adequate facilities, personnel, and patient population

This visit evaluates a site's suitability, assessing facilities, equipment, personnel, patient population, and GCP readiness.

Question 42: What is a Legally Authorized Representative (LAR)?

Regulatory authority representative
Sponsor's lawyer
An individual authorized to consent to research on behalf of someone who cannot consent themselves (Correct answer)
CRO project manager

Correct answer: An individual authorized to consent to research on behalf of someone who cannot consent themselves

A LAR is authorized under applicable law to consent on behalf of a person who lacks capacity.

Question 43: How long must investigators typically retain essential documents, including source documents, after a clinical trial is completed under FDA regulations?

2 years after the date of marketing approval or discontinuation of the IND (Correct answer)
10 years after the trial ends regardless of approval status
5 years after the last subject's last visit
1 year after study completion

Correct answer: 2 years after the date of marketing approval or discontinuation of the IND

Under 21 CFR 312.62, investigators must retain records for two years after marketing approval or, if approval is not sought, two years after discontinuation of the IND.

Question 44: Which FDA form is used by sponsors to submit expedited IND safety reports (individual case safety reports) to the agency?

FDA Form 3500A (MedWatch) (Correct answer)
FDA Form 356h (NDA Application)
FDA Form 2253 (Promotional Materials)
FDA Form 1572 (Statement of Investigator)

Correct answer: FDA Form 3500A (MedWatch)

FDA Form 3500A (MedWatch) is the mandatory reporting form used for expedited IND safety reports submitted to the FDA.

Question 45: What does GCP stand for in the context of clinical research?

Good Clinical Practice (Correct answer)
Global Compliance Protocol
General Clinical Procedures
Guided Clinical Pathways

Correct answer: Good Clinical Practice

GCP stands for Good Clinical Practice, an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials.

Question 46: What are source documents and why are they critical?

Marketing materials
Protocol copies sent to sites
Original records where data are first recorded, the basis for CRF verification (Correct answer)
Sponsor-only documents

Correct answer: Original records where data are first recorded, the basis for CRF verification

Source documents are all original records where trial data are first recorded, providing the verifiable basis for CRF data.

Question 47: What are data retention requirements?

Only electronic data
Destroy after study
At investigator's discretion
Retained for specified periods (typically 2+ years after marketing approval) per ICH, FDA, and local requirements (Correct answer)

Correct answer: Retained for specified periods (typically 2+ years after marketing approval) per ICH, FDA, and local requirements

Records must be retained per regulations: FDA requires 2 years after marketing approval; actual retention is often 15-25 years.

Question 48: A subject verbally reports a new symptom to site staff who document it in their notes but forget to enter it in the EDC for three weeks. Which ALCOA principle is most directly violated?

Contemporaneous (Correct answer)
Accurate
Legible
Complete

Correct answer: Contemporaneous

The three-week delay between observation and EDC entry violates the contemporaneous requirement that data be recorded at the time of the event.

Question 49: What is therapeutic misconception?

Deliberate deception
Disagreement about efficacy
The mistaken belief that all study aspects are for personal therapeutic benefit rather than science (Correct answer)
Medical error

Correct answer: The mistaken belief that all study aspects are for personal therapeutic benefit rather than science

When participants fail to distinguish between research goals and clinical care, compromising truly informed consent.

Question 50: What are the FDA's expedited programs for serious conditions?

Only oncology
Only one pathway
No expedited pathways
Four programs: Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review (Correct answer)

Correct answer: Four programs: Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review

Four programs: Fast Track (rolling review), Breakthrough Therapy (intensive guidance), Accelerated Approval (surrogate endpoints), Priority Review (6-month review).

Question 51: When enrolling prisoners in research, which additional federal regulation applies beyond standard informed consent requirements?

45 CFR 46 Subpart C (Correct answer)
21 CFR 312
45 CFR 46 Subpart D
21 CFR 50.25

Correct answer: 45 CFR 46 Subpart C

45 CFR 46 Subpart C specifically addresses additional protections for prisoners as a vulnerable population in research.

Question 52: What is a protocol deviation versus a protocol violation?

A deviation is more serious
They are the same thing
A deviation is any departure from the protocol; a violation is a deviation that affects safety or data integrity (Correct answer)
A violation only occurs when the sponsor makes changes

Correct answer: A deviation is any departure from the protocol; a violation is a deviation that affects safety or data integrity

A deviation is any unplanned departure from the protocol, while a violation is a significant deviation that may affect participant safety, rights, or data integrity.

Question 53: Which of the following is a key indicator that a site has a systemic protocol compliance problem rather than isolated deviations?

A single consent timing deviation that was immediately corrected
Recurring deviations of the same type across multiple subjects and multiple monitoring visits (Correct answer)
One deviation occurring in a single subject over a 3-year study
A deviation involving a laboratory timing window noted once

Correct answer: Recurring deviations of the same type across multiple subjects and multiple monitoring visits

Repeated deviations of the same type across multiple subjects and visits indicate a systemic process failure requiring root cause analysis and systemic corrective action.

Question 54: Which of the following best describes the investigator's documentation responsibilities for adverse events during a clinical trial?

Record only SAEs and omit non-serious AEs from source documents
Document only AEs that the investigator believes are drug-related
Record all observed and reported AEs with date of onset, severity, duration, outcome, and assessed relationship to study drug (Correct answer)
Summarize AEs at the end of the trial in the final study report only

Correct answer: Record all observed and reported AEs with date of onset, severity, duration, outcome, and assessed relationship to study drug

Investigators must comprehensively document all AEs in source records and on CRFs, capturing onset, severity, duration, action taken, outcome, and causality assessment for each event.

Question 55: What is 21CFR50.25 Subpart B?

Elements of Informed Consent (Correct answer)
Documentation of Emergency Use of Experimental Treatments
Documentation of Informed Consent
Exemptions of Informed Consent

Correct answer: Elements of Informed Consent

21 CFR 50.25, found within Subpart B, precisely outlines the 'Elements of Informed Consent' that must be provided to prospective research subjects. This section details the essential information, such as the study's purpose, risks, benefits, and alternatives, that must be communicated to ensure a subject can make an informed decision about participation. It serves as a cornerstone for ethical human subjects research.

Question 56: A purpose of monitoring clinical trials is to verify that:

The rights, safety, and well-being of human subjects are protected (Correct answer)
Investigators receive adequate payment for their participation in the clinical trial
The regulatory agency has received all case history information of subjects enrolled on the clinical trial
The investigator has received annual reports from the sponsor

Correct answer: The rights, safety, and well-being of human subjects are protected

A primary purpose of monitoring clinical trials is to verify that the rights, safety, and well-being of human subjects are protected. Monitors regularly visit study sites to ensure adherence to the protocol, Good Clinical Practice (GCP), and regulatory requirements. This oversight helps identify and address any issues that could compromise subject safety or ethical conduct.

Question 57: What is a Periodic Safety Update Report (PSUR)?

A daily safety log
A patient satisfaction survey
A periodic report providing comprehensive safety evaluation of a marketed product (Correct answer)
A one-time report at completion

Correct answer: A periodic report providing comprehensive safety evaluation of a marketed product

A PSUR (now PBRER per ICH E2C(R2)) provides periodic safety evaluation for marketed products.

Question 58: Which document serves as the primary record demonstrating that a monitoring visit occurred and what was reviewed?

The investigator's delegation log
The site initiation visit report
The protocol deviation log
The monitoring visit report (MVR) (Correct answer)

Correct answer: The monitoring visit report (MVR)

The monitoring visit report documents the date, scope, findings, follow-up actions, and confirms what source documents and data were reviewed.

Question 59: A CAPA (Corrective and Preventive Action) plan is developed in response to a protocol deviation. What is the PRIMARY purpose of the 'preventive' component?

To submit a protocol amendment to the FDA
To identify and address root causes to prevent recurrence of similar deviations (Correct answer)
To remove the affected subjects from the study analysis
To discipline the staff member who caused the deviation

Correct answer: To identify and address root causes to prevent recurrence of similar deviations

The preventive component of a CAPA focuses on identifying the root cause of the deviation and implementing systemic changes to prevent similar events from recurring.

Question 60: A clinical investigator must retain study records for how long after the investigation is discontinued or completed, per 21 CFR 312.62(c)?

7 years
2 years after the investigational drug is approved, or 2 years after shipment is discontinued (Correct answer)
5 years
3 years

Correct answer: 2 years after the investigational drug is approved, or 2 years after shipment is discontinued

Per 21 CFR 312.62(c), investigators must retain records for 2 years after the drug is approved for marketing or, if not approved, 2 years after the investigation is discontinued and FDA is notified.

Question 61: Which of the following is NOT a required element on the label of an investigational product according to 21 CFR 312.6?

The protocol code or study number.
A statement such as 'Caution: New Drug—Limited by Federal (or United States) law to investigational use.'
The name or identification code of the drug.
The name and address of the Principal Investigator. (Correct answer)

Correct answer: The name and address of the Principal Investigator.

21 CFR 312.6 specifies the labeling requirements for an investigational new drug. It requires a statement indicating the product is for investigational use. While GCP guidelines often lead to the inclusion of the protocol number, drug identifier, and sponsor information, the regulation does not explicitly require the Principal Investigator's name and address to be on the immediate product label; the sponsor's name and address is the standard requirement.

Question 62: An investigator is required to report SAEs to the IRB/IEC within what general timeframe under U.S. regulations?

24 hours of first awareness
30 calendar days of the event resolution
Only at annual continuing review
As specified in the IRB's own requirements, typically within 7 to 10 days (Correct answer)

Correct answer: As specified in the IRB's own requirements, typically within 7 to 10 days

While federal regulations do not specify a uniform timeframe for investigator-to-IRB SAE reporting, IRBs typically define their own requirements (often 7–10 days for serious unexpected events).

Question 63: A CAPA (Corrective and Preventive Action) plan issued after an audit finding should include all of the following EXCEPT:

Root cause analysis
Signatures from the FDA district office approving the plan (Correct answer)
Specific corrective actions to address the finding
A timeline for implementation and verification

Correct answer: Signatures from the FDA district office approving the plan

CAPAs are developed and approved internally by the sponsor or site; FDA district office signature is not a component of a standard CAPA document.

Question 64: The international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects is known as...

The ICH
The Declaration of Helsinki
Good Clinical Practice (GCP) (Correct answer)
Fundamental Ethical Principles (FEP)

Correct answer: Good Clinical Practice (GCP)

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human subjects. Adherence to GCP ensures the protection of the rights, safety, and well-being of trial subjects, and that the clinical trial data are credible and accurate. It is a globally recognized benchmark for ethical research.

Question 65: Under 21 CFR 312.32, a 'life-threatening adverse drug experience' is defined as one in which:

The event caused significant permanent disability
The subject required more than 24 hours of inpatient hospitalization
The subject was at immediate risk of death at the time of the adverse event (Correct answer)
The event required a surgical intervention to resolve

Correct answer: The subject was at immediate risk of death at the time of the adverse event

A life-threatening adverse drug experience is one where the subject was at immediate risk of dying at the time of the event — not one that hypothetically could have caused death.

Question 66: An investigator at a clinical trial site realizes that a study participant was inadvertently enrolled despite not meeting a key inclusion criterion. According to ICH GCP principles, what is the MOST appropriate immediate action for the investigator to take?

Wait for the next monitoring visit to discuss the issue with the Clinical Research Associate (CRA).
Continue the participant in the trial but exclude their data from the final analysis.
Take appropriate measures to protect the participant's safety and well-being, document the deviation, and report it to the sponsor and IRB/IEC as required. (Correct answer)
Inform the participant that they are being withdrawn from the study and document the event.

Correct answer: Take appropriate measures to protect the participant's safety and well-being, document the deviation, and report it to the sponsor and IRB/IEC as required.

ICH GCP emphasizes the paramount importance of protecting the rights, safety, and well-being of trial subjects. When a protocol deviation like this occurs, the investigator's first priority is the subject's safety. The investigator must then document the deviation and report it to the sponsor and the IRB/IEC according to their respective policies and regulatory requirements to ensure transparency and proper oversight.

Question 67: Which form is used in the United States for mandatory reporting of serious adverse events by investigators and manufacturers to the FDA?

FDA Form 1572
ICH E2B Individual Case Safety Report
CIOMS I Form
MedWatch Form 3500A (Correct answer)

Correct answer: MedWatch Form 3500A

The MedWatch Form 3500A is the FDA's mandatory reporting form for healthcare professionals, manufacturers, and distributors to report serious adverse events. The CIOMS I form is used for international submissions, FDA Form 1572 is the investigator statement of responsibilities, and ICH E2B is an electronic transmission standard.

Question 68: Which federal subpart specifically provides additional protections for prisoners as research subjects?

45 CFR 46 Subpart C (Correct answer)
45 CFR 46 Subpart B
45 CFR 46 Subpart A (The Common Rule)
45 CFR 46 Subpart D

Correct answer: 45 CFR 46 Subpart C

45 CFR 46 Subpart C specifically addresses additional protections for prisoners involved as research subjects.

Question 69: What must a principal investigator report to the IRB as an 'unanticipated problem'?

Any adverse event regardless of expectedness or relatedness
Only deaths occurring during the study
Any event that is unexpected, related or possibly related to the research, and suggests greater risk to subjects or others (Correct answer)
Adverse events that occur at other research sites only

Correct answer: Any event that is unexpected, related or possibly related to the research, and suggests greater risk to subjects or others

An unanticipated problem must be unexpected, related or possibly related to participation, and suggest a greater risk to subjects or others than previously known.

Question 70: What is the minimum IRB membership composition?

At least 5 members with diverse backgrounds, including one non-scientific and one unaffiliated member (Correct answer)
Only 2 physicians
Any number from one department
No requirements

Correct answer: At least 5 members with diverse backgrounds, including one non-scientific and one unaffiliated member

Per 21 CFR 56.107, at least 5 members with varying backgrounds including non-scientific and unaffiliated members.

Question 71: According to FDA regulations at 21 CFR 312.62, how long must an investigator retain records of protocol deviations for drugs studied under an IND?

7 years after the last enrolled subject completes the study
5 years after the last subject visit
2 years after the study is completed or discontinued, or 2 years after FDA approval (Correct answer)
1 year after study completion

Correct answer: 2 years after the study is completed or discontinued, or 2 years after FDA approval

21 CFR 312.62(c) requires investigators to retain records for 2 years following the date a marketing application is approved or 2 years after the investigation is discontinued.

Question 72: A certified copy of a source document is best described as:

A verified copy that preserves the content and meaning of the original, often with a certification statement (Correct answer)
A photocopy made by the site coordinator
A duplicate original signed by the investigator
Any electronic backup of paper records

Correct answer: A verified copy that preserves the content and meaning of the original, often with a certification statement

A certified copy is one that has been verified to be an exact and complete copy of the original, preserving all data and attributes.

Question 73: Under ICH E6(R2) Good Clinical Practice, which party bears primary responsibility for ensuring protocol compliance at the investigative site?

The Institutional Review Board (IRB)
The sponsor's Clinical Research Associate (CRA)
The Principal Investigator (PI) (Correct answer)
The FDA district office

Correct answer: The Principal Investigator (PI)

ICH E6(R2) Section 4.1 states the investigator is responsible for conducting the trial in compliance with the protocol agreed to by the sponsor and approved by the IRB.

Question 74: When does the Common Rule (45 CFR 46 Subpart A) apply to research?

Only to FDA-regulated research
When more than 100 subjects are enrolled
Only to privately funded research
When research is conducted or supported by a federal department or agency (Correct answer)

Correct answer: When research is conducted or supported by a federal department or agency

The Common Rule applies to research that is conducted or supported by any federal department or agency that has adopted it.

Question 75: According to ICH GCP E6(R2), if the sponsor does not provide specific written instructions on when trial-related records can be destroyed, what is the minimum period the investigator/institution must retain essential documents, including source documents?

Until the study has been published in a peer-reviewed journal.
For at least 2 years after the last approval of a marketing application in an ICH region, or after development is formally discontinued. (Correct answer)
Indefinitely, as part of the subject's permanent medical record.
For exactly 5 years after the last subject completes their final visit.

Correct answer: For at least 2 years after the last approval of a marketing application in an ICH region, or after development is formally discontinued.

ICH GCP E6(R2) Section 4.9.5 and 5.5.12 state that essential documents should be retained for at least 2 years after the last approval of a marketing application in an ICH region, or until there are no pending applications, or for at least 2 years after the formal discontinuation of the investigational product's development. This ensures data is available for regulatory review for a sufficient period.

Question 76: A temperature excursion is discovered after IP has been stored at the site for two weeks. What should the CRC do?

Continue using the IP since two weeks have passed without incident
Discard the IP immediately and reorder
Quarantine the affected IP and notify the sponsor immediately for guidance (Correct answer)
Dispense remaining IP before reporting the excursion

Correct answer: Quarantine the affected IP and notify the sponsor immediately for guidance

Affected IP must be quarantined and the sponsor notified immediately; only the sponsor can determine whether the product remains suitable for use.

Question 77: A CRA discovers discrepancies between the source data and the CRF during a monitoring visit. Under ICH GCP, the monitor should:

Correct the CRF entries directly without investigator involvement
Inform the sponsor's legal team only, treating the information as confidential
Document the discrepancies in the monitoring report and request corrections through the investigator (Correct answer)
Report the discrepancies directly to the IEC and request a site suspension

Correct answer: Document the discrepancies in the monitoring report and request corrections through the investigator

ICH E6 requires monitors to document data discrepancies in visit reports and ensure that only authorized site personnel make and initial corrections to source documents and CRFs.

Question 78: Which of the following best describes a 'suspected adverse reaction' in the context of IND safety reporting?

An AE that resolves without medical intervention
Any AE occurring after the first dose regardless of relationship
An AE that is listed in the Investigator's Brochure as expected
An AE for which there is a reasonable possibility of a causal relationship to the investigational drug (Correct answer)

Correct answer: An AE for which there is a reasonable possibility of a causal relationship to the investigational drug

A suspected adverse reaction is any AE for which there is a reasonable possibility that the investigational drug caused the event, based on available evidence and clinical judgment.

Question 79: According to ICH GCP, a sponsor who transfers trial-related duties to a CRO must ensure that:

The CRO is clearly specified as the trial sponsor in all documents
The CRO independently reviews and approves all protocol amendments
All transferred obligations are specified in writing and the sponsor retains ultimate responsibility (Correct answer)
The CRO assumes all legal liability for the sponsor's regulatory obligations

Correct answer: All transferred obligations are specified in writing and the sponsor retains ultimate responsibility

ICH E6 section 5.2 states that CRO responsibilities must be documented in writing, but the sponsor retains ultimate responsibility for trial quality and compliance.

Question 80: A subject wants to withdraw from a study but is concerned their medical records will be erased. What must the investigator explain?

Data already collected may still be used, but no new data will be collected (Correct answer)
Withdrawal nullifies all prior data
Records will be destroyed upon withdrawal
Only the sponsor can decide whether to retain the data

Correct answer: Data already collected may still be used, but no new data will be collected

Subjects may withdraw at any time without penalty, but data collected prior to withdrawal may be retained and used per regulatory requirements.

Question 81: Under ICH GCP, an investigator who delegates trial tasks to study staff must ensure that:

Delegation is limited to licensed healthcare professionals only
All staff are aware that the investigator alone takes responsibility
Each delegate is qualified and adequately trained for the assigned tasks (Correct answer)
Each delegate holds a medical license

Correct answer: Each delegate is qualified and adequately trained for the assigned tasks

ICH E6 section 4.2 requires investigators to ensure that any delegated individuals are qualified and trained for the specific tasks they perform.

Question 82: Under ICH GCP, what does the concept of 'direct access' grant to monitors, auditors, and inspectors?

Permission to examine, analyze, verify, and reproduce any records related to the trial (Correct answer)
Authority to modify source documents to correct errors
Access to the sponsor's commercially confidential manufacturing data
The right to interview subjects without the investigator's knowledge

Correct answer: Permission to examine, analyze, verify, and reproduce any records related to the trial

Direct access under ICH E6 means that authorized oversight personnel may examine, analyze, verify, and reproduce any records pertinent to the trial at the trial site.

Question 83: Under 21 CFR Part 56, what is the minimum number of members required for an Institutional Review Board (IRB)?

Ten members
Three members
Seven members
Five members (Correct answer)

Correct answer: Five members

21 CFR 56.107(a) specifies that each IRB must have at least five members with sufficiently diverse backgrounds, including at least one member with primarily scientific expertise and one with primarily nonscientific expertise, to allow adequate review.

Question 84: Under 21 CFR 312.305, expanded access (compassionate use) for an individual patient in an emergency requires which of the following before treatment may begin?

A pre-IND meeting with FDA and sponsor agreement
IRB approval, sponsor consent, and a signed patient waiver
FDA verbal authorization, with a written protocol submission within 15 days (Correct answer)
Full IND submission and 30-day FDA review period

Correct answer: FDA verbal authorization, with a written protocol submission within 15 days

For emergency individual patient expanded access, FDA may authorize treatment verbally or via other rapid means; the IND or protocol may be submitted within 15 working days after authorization.

Question 85: During a monitoring visit, the CRA finds that the investigator's brochure (IB) version in the regulatory binder is two versions old. What should the CRA do?

Provide the current IB version, document the finding, and ensure the IRB receives the updated version (Correct answer)
Accept it because older versions are still valid references
Immediately halt subject dosing until the binder is updated
Note it as a protocol deviation and file it in the monitoring log

Correct answer: Provide the current IB version, document the finding, and ensure the IRB receives the updated version

The CRA should supply the current IB, document the discrepancy as a finding, and confirm the IRB has approved the updated version as required.

Question 86: What is investigational product accountability?

Cost of the drug
Only pharmacist responsibility
Only for controlled substances
A system tracking all IP from receipt through dispensing, use, return, and disposition (Correct answer)

Correct answer: A system tracking all IP from receipt through dispensing, use, return, and disposition

Drug accountability tracks the entire lifecycle of IP at a site.

Question 87: Which of the following is considered a 'vulnerable population' requiring additional protections in research?

Healthy adult volunteers aged 25-40
Participants in a fitness study
Faculty members at research universities
Economically disadvantaged individuals who may be unduly influenced by payment (Correct answer)

Correct answer: Economically disadvantaged individuals who may be unduly influenced by payment

Economically disadvantaged individuals may be vulnerable to undue influence from financial incentives, requiring additional safeguards in research participation.

Question 88: In a non-emergency situation, under which of the following conditions, if any, may subjects been rolled into a study prior to IRB/IEC approval?

At least one member's primary area of interest is in a nonscientific area (Correct answer)
A majority of the members are from or have ties to the institution of record
At least one member holds a Ph.D. degree or equivalent
A majority of the members'primary area of interest is in a scientific area

Correct answer: At least one member's primary area of interest is in a nonscientific area

For an IRB to be properly constituted and capable of reviewing research, it must include at least one member whose primary area of interest is in a nonscientific area. This requirement ensures that the IRB considers the perspectives of the general public and non-scientific ethical concerns, balancing scientific rigor with broader societal values. This diversity helps ensure a comprehensive ethical review of research.

Question 89: What happens when an FDA inspection results in a Form 483?

Site is closed immediately
The FDA issues observations of conditions that may constitute violations requiring corrective actions (Correct answer)
No action required
Drug is approved

Correct answer: The FDA issues observations of conditions that may constitute violations requiring corrective actions

Form 483 lists inspectional observations of conditions that may constitute violations. Sites should respond within 15 business days.

Question 90: What is SDV's role in data quality?

Only checks demographics
Only at trial end
Comparing CRF data against source documents to confirm accuracy, completeness, and consistency (Correct answer)
Optional and rarely performed

Correct answer: Comparing CRF data against source documents to confirm accuracy, completeness, and consistency

SDV involves monitors comparing CRF entries against original source documents.

Question 91: When a U.S.-funded clinical trial is conducted in a developing country, the ethical standard for participant protections must be:

At least equivalent to the standards that would apply in the United States (Correct answer)
Only the local country's minimum legal requirements
Determined solely by the international sponsor
Set by the local community leaders without external input

Correct answer: At least equivalent to the standards that would apply in the United States

The Common Rule and ICH GCP require that research conducted abroad with U.S. funding afford protections equivalent to those required domestically.

Question 92: What are key responsibilities during a routine monitoring visit?

Verifying consent, source data, protocol compliance, drug accountability, AE reporting, and document maintenance (Correct answer)
Only checking drug supply
Only meeting the PI
Just collecting CRFs

Correct answer: Verifying consent, source data, protocol compliance, drug accountability, AE reporting, and document maintenance

CRAs verify informed consent, perform SDV, assess compliance, check drug accountability, review AE reporting, and ensure documents are maintained.

Question 93: During a clinical trial, a subject's study medication is accidentally swapped with another subject's medication. Although both subjects received the wrong dose for one day, neither experienced any adverse effects. This event was unexpected and not outlined in the protocol's risk section. This event should be promptly reported to the IRB as:

An unanticipated problem involving risks to subjects or others (UAP). (Correct answer)
An anticipated adverse event.
A minor protocol deviation not requiring prompt reporting.
A significant new finding to be shared only at continuing review.

Correct answer: An unanticipated problem involving risks to subjects or others (UAP).

An unanticipated problem involving risks to subjects or others (UAP) is any incident, experience, or outcome that is (1) unexpected, (2) related or possibly related to participation in the research, and (3) suggests that the research places subjects or others at a greater risk of harm than was previously known. A medication swap, even without immediate harm, fits this definition because it was unexpected and exposed subjects to potential risks not previously recognized, and must be reported promptly.

Question 94: What is the primary purpose of having a non-scientist member on an IRB?

To review financial disclosures
To serve as a tiebreaker in votes
To represent community and non-scientific perspectives in the review (Correct answer)
To ensure statistical validity of the protocol

Correct answer: To represent community and non-scientific perspectives in the review

Non-scientist members bring community and lay perspectives that help the IRB evaluate ethical issues beyond scientific merit.

Question 95: During a regulatory inspection, the inspector requests immediate access to the TMF. The sponsor's TMF is electronic. What must the sponsor be able to demonstrate?

That paper backups exist for all electronic documents
That only the CRA has access to the eTMF
That the eTMF system is validated, audit trails are intact, and documents are legible and complete (Correct answer)
That the eTMF was created after study closure

Correct answer: That the eTMF system is validated, audit trails are intact, and documents are legible and complete

For an eTMF, sponsors must demonstrate system validation, intact audit trails, document legibility, and completeness to satisfy regulatory inspection.

Question 96: Which GCP principle underlies the requirement that investigators retain source documents?

Regulatory authorities must be able to reconstruct and evaluate the trial's conduct and data integrity through retained records (Correct answer)
Subjects have the right to receive copies of their own source documents on demand
IRB approval depends on availability of all source documents at all times
The investigator must demonstrate financial compliance to the sponsor

Correct answer: Regulatory authorities must be able to reconstruct and evaluate the trial's conduct and data integrity through retained records

GCP requires document retention to allow regulatory authorities to audit and verify that the trial was conducted properly and that data are reliable.

Question 97: A subject requires emergency treatment that deviates from the study protocol to prevent immediate harm. What must happen?

The deviation must be documented, and the sponsor and IRB must be notified as soon as possible (Correct answer)
The investigator must obtain sponsor approval before administering emergency treatment
No action is required if the subject recovers fully
The deviation should not be documented to protect the subject's privacy

Correct answer: The deviation must be documented, and the sponsor and IRB must be notified as soon as possible

Emergency protocol deviations must be documented and reported to the sponsor and IRB as soon as possible after the emergency, even though prior approval was not possible.

Question 98: What is the role of the sponsor in a clinical trial?

To initiate, manage, and finance the clinical trial (Correct answer)
To treat patients
To review protocols as an ethics committee
To manufacture all medications

Correct answer: To initiate, manage, and finance the clinical trial

The sponsor takes responsibility for initiating, managing, and/or financing a clinical trial.

Question 99: ICH E6(R2) Section 5.20.1 states that a sponsor's Quality Management System should include risk-based approaches. How does this apply to protocol deviation management?

Sponsors should focus oversight resources on deviations that pose the greatest risk to subject safety and data reliability (Correct answer)
All deviations must be treated equally regardless of their impact on subject safety
Only deviations identified by the FDA need to be included in quality management
Risk-based monitoring eliminates the need to report deviations to the IRB

Correct answer: Sponsors should focus oversight resources on deviations that pose the greatest risk to subject safety and data reliability

ICH E6(R2) emphasizes risk-based quality management, which means sponsors and sites should prioritize resources to address deviations with the greatest potential impact on subject safety and data integrity.

Question 100: A researcher modifies the study protocol to add a new data collection questionnaire. What must occur before implementing this change?

Notify the sponsor only
Implement the change immediately and report it at the next continuing review
Inform participants verbally and document it in their records
Obtain IRB approval of the amendment, then implement (Correct answer)

Correct answer: Obtain IRB approval of the amendment, then implement

Protocol amendments must be reviewed and approved by the IRB before implementation, except when necessary to eliminate immediate hazard.

Question 101: Under ICH E6, what action is required when a significant protocol amendment is made after IEC approval?

Submit the amendment only to the regulatory authority
Implement the change and notify the IEC at the next continuing review
Notify the IEC within 30 days but continue the trial
Obtain IEC approval before implementing the amendment (Correct answer)

Correct answer: Obtain IEC approval before implementing the amendment

ICH E6 section 4.10.2 requires that amendments which may affect subject safety or study conduct be approved by the IEC before implementation.

Question 102: What is the Declaration of Helsinki?

A US federal regulation governing clinical trials
A pharmacovigilance reporting standard
A guideline for manufacturing investigational drugs
A set of ethical principles for medical research involving human subjects (Correct answer)

Correct answer: A set of ethical principles for medical research involving human subjects

The Declaration of Helsinki is a statement of ethical principles developed by the World Medical Association to guide medical research involving human subjects.

Question 103: Which element is MOST important to include in a protocol deviation report submitted to the IRB?

The investigator's personal opinion about whether the deviation was avoidable
A description of the deviation, the impact on subject safety/data integrity, and corrective actions taken (Correct answer)
The financial cost of the deviation to the sponsor
A request for additional funding to prevent future deviations

Correct answer: A description of the deviation, the impact on subject safety/data integrity, and corrective actions taken

IRB deviation reports must describe what occurred, assess the impact on subject safety and data integrity, and outline corrective/preventive actions to be taken.

Question 104: What are the ALCOA+ principles for data integrity?

A statistical method
An AE classification scale
A drug classification
Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available (Correct answer)

Correct answer: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available

ALCOA+ defines data integrity: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available.

Question 105: Which element of informed consent must be disclosed when a study involves more than minimal risk?

The sponsor's financial projections
The investigator's publication record
Names of all IRB members
Compensation available for research-related injury (Correct answer)

Correct answer: Compensation available for research-related injury

21 CFR 50.25(a)(6) requires disclosure of compensation and medical treatment available if injury occurs in studies involving more than minimal risk.

Question 106: When should unblinding occur?

Only in medical emergencies when treatment knowledge is essential for patient care (Correct answer)
Every visit
Sponsor can unblind anytime
Whenever participant requests

Correct answer: Only in medical emergencies when treatment knowledge is essential for patient care

Unblinding should only occur in medical emergencies when knowing treatment is essential for medical management.

Question 107: What essential documents must be in the investigator site file?

Only the protocol
All documents permitting evaluation of trial conduct and data quality (Correct answer)
Only consent forms
Only the drug log

Correct answer: All documents permitting evaluation of trial conduct and data quality

Essential documents include all records that permit evaluation of the trial and the quality of data produced.

Question 108: Under 21 CFR 312.66, an investigator must promptly report to the IRB any protocol deviations made to:

Reduce administrative burden on the site staff
Eliminate apparent immediate hazards to human subjects (Correct answer)
Accommodate sponsor requests for accelerated enrollment
Simplify the subject visit schedule for convenience

Correct answer: Eliminate apparent immediate hazards to human subjects

21 CFR 312.66 specifically requires investigators to report to the IRB any deviations from the approved protocol made to eliminate apparent immediate hazards to the human subjects.

Question 109: How should researchers handle incidental findings?

Ignore them
Only sponsor decides
They never occur
Have a predetermined plan for managing clinically significant findings, including disclosure (Correct answer)

Correct answer: Have a predetermined plan for managing clinically significant findings, including disclosure

Ethical practice requires a prospective plan for managing incidental findings with criteria for significance and disclosure procedures.

Question 110: What is single IRB (sIRB) review?

Only international trials
Never required
Each site needs its own IRB
One IRB for all sites in a multi-site study, required for NIH-funded multi-site research (Correct answer)

Correct answer: One IRB for all sites in a multi-site study, required for NIH-funded multi-site research

sIRB uses one IRB for all sites, required by the 2018 Revised Common Rule and NIH policy for multi-site US research.

Question 111: Under 21 CFR Part 50 Subpart D, which population is classified as a 'vulnerable subject' requiring additional protections in FDA-regulated research?

Prisoners, as defined by 21 CFR 50.3(f) (Correct answer)
Subjects with chronic diseases enrolled in Phase III trials
Healthy volunteers over age 65
Foreign nationals enrolled at international sites

Correct answer: Prisoners, as defined by 21 CFR 50.3(f)

21 CFR Part 50 Subpart D provides additional consent protections specifically for prisoners because their incarceration may affect voluntariness of participation.

Question 112: How long must an IRB retain records of research activities, including minutes of convened meetings, under federal regulations?

Five years from the date of initial IRB approval
Indefinitely, with no minimum retention period specified
One year after study completion
At least three years after completion of the research (Correct answer)

Correct answer: At least three years after completion of the research

45 CFR 46.115(b) requires that IRB records, including minutes, membership rosters, and study files, be retained for at least three years after completion of the research. This ensures accountability and the ability to reconstruct IRB decisions during audits or investigations.

Question 113: A site's IP supply falls below the minimum threshold defined by the sponsor. What should the CRC do?

Contact the IRT/sponsor to trigger a resupply shipment before enrollment is disrupted (Correct answer)
Reduce each subject's dose to stretch supply
Continue enrolling subjects until IP runs out
Borrow IP from another site

Correct answer: Contact the IRT/sponsor to trigger a resupply shipment before enrollment is disrupted

Sites must proactively monitor inventory and initiate resupply through the IRT or sponsor before reaching critically low levels to avoid enrollment interruptions.

Question 114: An investigator fails to report a serious adverse event to the sponsor within the ICH GCP-required timeframe. This is considered a:

Non-issue if the event resolved without sequelae
Significant protocol deviation with potential regulatory and ethical consequences (Correct answer)
Minor protocol deviation that can be noted in the study close-out report
Administrative error correctable by a sponsor waiver

Correct answer: Significant protocol deviation with potential regulatory and ethical consequences

Failure to report SAEs within the required timelines is a significant GCP deviation that can compromise subject safety and data integrity, with regulatory consequences.

Question 115: A sponsor conducting a Phase III trial discovers that an investigator site has been enrolling subjects without obtaining informed consent. Under 21 CFR 312.70, what action may FDA take?

Disqualify the investigator from receiving investigational drugs (Correct answer)
Require the sponsor to retrain all site personnel
Suspend the IND pending re-consent of all enrolled subjects
Issue a warning letter requiring corrective action within 30 days

Correct answer: Disqualify the investigator from receiving investigational drugs

Under 21 CFR 312.70, FDA may disqualify a clinical investigator from receiving investigational new drugs if the investigator repeatedly or deliberately fails to comply with applicable regulations.

Question 116: What is an FDA Warning Letter?

Drug approval letter
Routine communication
Successful inspection notification
An official correspondence citing significant regulatory violations requiring prompt corrective action (Correct answer)

Correct answer: An official correspondence citing significant regulatory violations requiring prompt corrective action

A Warning Letter identifies significant violations that may lead to enforcement action if not corrected.

Question 117: During the informed consent process, the investigator must ensure that the potential participant understands all of the following EXCEPT:

The complete formulation and manufacturing process of the investigational product. (Correct answer)
That their participation is voluntary and they may withdraw at any time.
That the trial involves research and the purpose of the trial.
The trial procedures, foreseeable risks, and potential benefits.

Correct answer: The complete formulation and manufacturing process of the investigational product.

ICH GCP E6(R2) Section 4.8.10 details the elements that must be included in the informed consent discussion and form. These elements focus on ensuring the participant can make a voluntary and informed decision. They include the study's purpose, procedures, risks, benefits, and the voluntary nature of participation. While the Investigator's Brochure provides detailed product information to the investigator, the complete proprietary manufacturing process is not a required element for the participant's informed consent.

Question 118: Which of the following criteria qualifies an adverse event as 'serious' (SAE) under ICH E6 GCP guidelines?

Any adverse event that causes a subject to miss a scheduled study visit
An adverse event resulting in death, hospitalization, persistent disability, or congenital anomaly (Correct answer)
An adverse event occurring in more than 5% of the study population
Any adverse event requiring a protocol-specified dose reduction

Correct answer: An adverse event resulting in death, hospitalization, persistent disability, or congenital anomaly

ICH E6 defines a serious adverse event as one that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or constitutes an important medical event requiring intervention to prevent one of these outcomes.

Question 119: During an FDA inspection, the inspector requests access to the electronic medical records (EMR) of enrolled subjects, which are the designated source documents. The site staff should:

Tell the inspector to request the records directly from the hospital's legal department.
Refuse access, stating that EMRs are confidential hospital property and not subject to FDA review.
Provide direct, supervised access to the relevant sections of the EMR for the subjects who provided consent. (Correct answer)
Print out every page of the subjects' entire medical history for the inspector to review.

Correct answer: Provide direct, supervised access to the relevant sections of the EMR for the subjects who provided consent.

Investigators are required by regulation (e.g., 21 CFR 312.68) to permit FDA representatives to access, copy, and verify records related to the clinical investigation. [23] This includes providing supervised access to EMRs that serve as source documentation. Refusing access is a serious regulatory violation. [23]

Question 120: The Nuremberg Code was developed primarily in response to which historical event?

Nazi medical experiments conducted on prisoners during World War II (Correct answer)
Thalidomide birth defect crisis of the 1950s–60s
Willowbrook hepatitis studies involving children with intellectual disabilities
Unethical syphilis experiments on African American men in Alabama

Correct answer: Nazi medical experiments conducted on prisoners during World War II

The Nuremberg Code (1947) was established after the Nuremberg Doctors' Trial revealed the atrocities of Nazi medical experimentation.

Question 121: How is a 'certified copy' of a source document defined under ICH E6 GCP?

A photocopy reviewed and stamped by the principal investigator as accurate
A digital scan uploaded to a validated electronic document management system
A document notarized by a legal authority confirming the investigator's signature is authentic
A verified copy confirmed to be an exact reproduction of the original, preserving all content and context (Correct answer)

Correct answer: A verified copy confirmed to be an exact reproduction of the original, preserving all content and context

A certified copy is any copy — paper, microfilm, or electronic — that has been verified to contain all the same information as the original, including data describing its context, content, and structure. Verification confirms the copy is a true and complete reproduction.

Question 122: What is the significance of ICH E6(R2) vs the original?

R2 only applies in Europe
No differences
R2 introduced risk-based monitoring, quality management, and updated electronic records requirements (Correct answer)
R2 eliminated consent

Correct answer: R2 introduced risk-based monitoring, quality management, and updated electronic records requirements

R2 introduced risk-based monitoring, quality management, updated electronic records requirements, and proportionate risk-based approaches.

Question 123: When pregnant women are enrolled in research under 45 CFR 46 Subpart B, whose consent is generally required?

Only the IRB's approval is needed
Consent of the pregnant woman alone is sufficient (Correct answer)
Consent of both the pregnant woman and the father is always required
The LAR of the unborn child must consent

Correct answer: Consent of the pregnant woman alone is sufficient

45 CFR 46 Subpart B generally requires consent of the pregnant woman alone for research involving pregnant women; father's consent is only required in limited specific circumstances.

Question 124: During source data verification (SDV), the CRA finds that a lab value recorded in the CRF is different from the value in the laboratory report. This is an example of:

A data discrepancy requiring a query (Correct answer)
An adverse event
A protocol deviation
A serious breach

Correct answer: A data discrepancy requiring a query

A transcription error between source data and the CRF is a data discrepancy that should be resolved through the query process.

Question 125: The 'Enduring' attribute added to ALCOA+ means that source data must be:

Backed up daily to a cloud server
Stored in a way that it remains readable and accessible for the required retention period (Correct answer)
Reviewed by the sponsor at least annually
Submitted to the FDA within a defined timeframe

Correct answer: Stored in a way that it remains readable and accessible for the required retention period

Enduring means data must be stored in durable formats that remain legible and retrievable throughout the required retention period.

Question 126: Which of the following constitutes research misconduct as defined by federal regulations?

Disagreeing with peer reviewers about data interpretation
Fabrication, falsification, or plagiarism in proposing, performing, or reporting research (Correct answer)
Making an honest error in data analysis later corrected
Publishing preliminary findings before peer review

Correct answer: Fabrication, falsification, or plagiarism in proposing, performing, or reporting research

Federal policy defines research misconduct as fabrication, falsification, or plagiarism (FFP) in research activities; honest error and differences of opinion are excluded.

Question 127: When a protocol deviation is identified during a monitoring visit, the Clinical Research Associate (CRA) should FIRST:

Document the finding in the monitoring report and discuss corrective actions with the PI (Correct answer)
Suspend all study activities at the site until the deviation is resolved
Immediately notify the IRB before informing the sponsor
Report the deviation directly to the FDA without notifying the site

Correct answer: Document the finding in the monitoring report and discuss corrective actions with the PI

The CRA should document the finding in the monitoring report and work with the investigator to implement corrective and preventive actions (CAPA), per standard sponsor monitoring procedures.

Question 128: A participant in a cross-cultural study belongs to a community where individual decision-making is traditionally deferred to a community elder. The ethical approach to informed consent in this context is to:

Obtain consent via proxy from the elder without participant involvement
Obtain only the elder's permission and forgo individual consent
Exclude communities with communal decision-making from research
Respect community consultation processes while still ensuring individual participants provide voluntary personal consent (Correct answer)

Correct answer: Respect community consultation processes while still ensuring individual participants provide voluntary personal consent

Cultural practices must be respected, but individual voluntary consent remains a non-negotiable ethical requirement; community approval supplements but does not replace personal consent.

Question 129: Which action triggers a requirement for PROMPT reporting to the IRB?

A change in the study sponsor's contact information
A minor protocol deviation with no effect on subject safety
An unanticipated problem involving risks to subjects or others (Correct answer)
Enrollment of the final study subject

Correct answer: An unanticipated problem involving risks to subjects or others

Unanticipated problems involving risks to subjects or others must be reported promptly to the IRB, institution, and applicable regulatory bodies.

Question 130: Which of the following best describes the ethical principle of 'equipoise' as it applies to clinical trials?

A genuine state of uncertainty in the expert medical community about the comparative merits of experimental and control treatments (Correct answer)
Ensuring equal access to the experimental treatment after the trial ends
Ensuring equal numbers of participants are assigned to each study arm
Balancing financial payments equally among all research sites

Correct answer: A genuine state of uncertainty in the expert medical community about the comparative merits of experimental and control treatments

Equipoise means there is genuine uncertainty about which treatment arm is superior, which ethically justifies randomizing participants between them.

SOCRA CCRP — Certified Clinical Research Professional

The SOCRA CCRP exam is a 130-question certification assessment for clinical research professionals, covering U.S. federal regulations, ICH Good Clinical Practice guidelines, and ethical principles across the full clinical trial lifecycle.

130

Questions

240 min

Time Limit

71%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds